nach oben

Journal of Clinical Immunology

Erschienen in:

01.03.2010

Natural Hidden Autoantibodies to Tissue Transglutaminase Cross-React with Fibrinogen

verfasst von: Ingrid M. Zöller-Utz, Birgit Esslinger, Anja Schulze-Krebs, Walburga Dieterich

Erschienen in: Journal of Clinical Immunology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Patients with celiac disease display autoantibodies against tissue transglutaminase (TG2), and the high sensitivity and specificity of these autoantibodies render them a reliable tool for diagnosis. However, we found that denatured sera from healthy persons also showed reactivity against TG2.

Methods

To further examine the specificity of this phenomenon, sera of healthy individuals and celiac patients were denatured by heat or pH shift.

Results and discussion

Denatured sera of all individuals showed autoantibodies against TG2 in ELISA that could be specifically inhibited by TG2, but the biological role of these autoantibodies remains unknown. The alpha fibrinogen precursor could be isolated as serum protein that reacts with TG2 antibodies and treated sera reacted with fibrinogen in Western blotting. Cross-reactivity of TG2 antibodies with fibrinogen and vice versa was observed.

Conclusion

We hypothesise that denaturation of sera reveals hidden autoantibodies against TG2, which might be normally masked by fibrinogen.

Green PH, Jabri B. Coeliac disease. Lancet. 2003;362:383–91. CrossRefPubMed

Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology. 1992;102:330–54. PubMed

Trier JS. Celiac sprue. N Engl J Med. 1991;325:1709–19. PubMed

Catassi C, Kryszak D, Louis-Jacques O, Duerksen DR, Hill I, Crowe SE, et al. Detection of Celiac disease in primary care: a multicenter case-finding study in North America. Am J Gastroenterol. 2007;102:1454–60. CrossRefPubMed

Dube C, Rostom A, Sy R, Cranney A, Saloojee N, Garritty C, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology. 2005;128:S57–67. CrossRefPubMed

Guandalini S. The influence of gluten: weaning recommendations for healthy children and children at risk for celiac disease. Nestle Nutr Workshop Ser Pediatr Program. 2007;60:139–51. discussion 151-135. CrossRefPubMed

Norris JM, Barriga K, Hoffenberg EJ, Taki I, Miao D, Haas JE, et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA. 2005;293:2343–51. CrossRefPubMed

Carlsson A, Agardh D, Borulf S, Grodzinsky E, Axelsson I, Ivarsson SA. Prevalence of celiac disease: before and after a national change in feeding recommendations. Scand J Gastroenterol. 2006;41:553–8. CrossRefPubMed

Stene LC, Honeyman MC, Hoffenberg EJ, Haas JE, Sokol RJ, Emery L, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol. 2006;101:2333–40. CrossRefPubMed

10.

Troncone R, Auricchio S. Rotavirus and celiac disease: clues to the pathogenesis and perspectives on prevention. J Pediatr Gastroenterol Nutr. 2007;44:527–8. CrossRefPubMed

11.

Sollid LM. Molecular basis of celiac disease. Annu Rev Immunol. 2000;18:53–81. CrossRefPubMed

12.

Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3:797–801. CrossRefPubMed

13.

Dieterich W, Laag E, Schopper H, Volta U, Ferguson A, Gillett H, et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology. 1998;115:1317–21. CrossRefPubMed

14.

Wong RC, Wilson RJ, Steele RH, Radford-Smith G, Adelstein S. A comparison of 13 guinea pig and human anti-tissue transglutaminase antibody ELISA kits. J Clin Pathol. 2002;55:488–94. PubMed

15.

Brownlee AA, Lockwood CM. Heat treatment of normal human sera reveals antibodies to bactericidal permeability-inducing protein (BPI). Clin Exp Immunol. 1999;117:183–9. CrossRefPubMed

16.

Cancado EL, Abrantes-Lemos CP, Vilas-Boas LS, Novo NF, Carrilho FJ, Laudanna AA. Thermolabile and calcium-dependent serum factor interferes with polymerized actin, and impairs anti-actin antibody detection. J Autoimmun. 2001;17:223–8. CrossRefPubMed

17.

Soltis RD, Hasz D, Morris MJ, Wilson ID. The effect of heat inactivation of serum on aggregation of immunoglobulins. Immunology. 1979;36:37–45. PubMed

18.

D'Cruz DP, Keser G, Direskeneli H, Khamashta MA, Hughes GR. Anti-endothelial cell antibodies in systemic vasculitis and systemic lupus erythematosus (SLE): effects of heat inactivation on binding and specificity. Clin Exp Immunol. 1999;115:567–70. CrossRefPubMed

19.

Jungkind DL, DiRenzo SA, Young SJ. Effect of using heat-inactivated serum with the Abbott human T-cell lymphotropic virus type III antibody test. J Clin Microbiol. 1986;23:381–2. PubMed

20.

Hasselaar P, Triplett DA, LaRue A, Derksen RH, Blokzijl L, de Groot PG, et al. Heat treatment of serum and plasma induces false positive results in the antiphospholipid antibody ELISA. J Rheumatol. 1990;17:186–91. PubMed

21.

Cheng HM, Ngeow YF, Sam CK. Heat inactivation of serum potentiates anti-cardiolipin antibody binding in ELISA. J Immunol Methods. 1989;124:235–8. CrossRefPubMed

22.

Cheng HM, Chamley L. Cryptic natural autoantibodies and co-potentiators. Autoimmun Rev. 2008;7:431–4. CrossRefPubMed

23.

Cheng HM. Antiphospholipid antibodies are masked in normal human serum. Immunol Today. 1991;12:96. CrossRefPubMed

24.

Dieterich W, Trapp D, Esslinger B, Leidenberger M, Piper J, Hahn E, et al. Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity. Gut. 2003;52:1562–6. CrossRefPubMed

25.

Agardh D, Roth B, Lernmark A, Stenberg P. Calcium activation of tissue transglutaminase in radioligand binding and enzyme-linked autoantibody immunoassays in childhood celiac disease. Clin Chim Acta. 2005;358:95–103. CrossRefPubMed

26.

Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J. 2002;368:377–96. CrossRefPubMed

27.

Mitkevich OV, Shainoff JR, DiBello PM, Yee VC, Teller DC, Smejkal GB, et al. Coagulation factor XIIIa undergoes a conformational change evoked by glutamine substrate. Studies on kinetics of inhibition and binding of XIIIA by a cross-reacting antifibrinogen antibody. J Biol Chem. 1998;273:14387–91. CrossRefPubMed

28.

Bussone G, Dib H, Dimitrov JD, Camoin L, Broussard C, Tamas N, et al. Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations. Proteomics. 2009;9:2253–62. CrossRefPubMed

29.

Djoumerska I, Tchorbanov A, Pashov A, Vassilev T. The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used. Scand J Immunol. 2005;61:357–63. CrossRefPubMed

30.

Dimitrov JD, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. Transition towards antigen-binding promiscuity of a monospecific antibody. Mol Immunol. 2007;44:1854–63. CrossRefPubMed

31.

Labrousse H, Adib-Conquy M, Avrameas S. Effect of temperature on the reactivities of polyreactive and monospecific monoclonal IgG antibodies. Res Immunol. 1997;148:267–76. CrossRefPubMed

32.

Abu-Shakra M, Shoenfeld Y. Natural hidden autoantibodies. Isr Med Assoc J. 2007;9:748–9. PubMed

33.

Kra-Oz Z, Lorber M, Shoenfeld Y, Scharff Y. Inhibitor(s) of natural anti-cardiolipin autoantibodies. Clin Exp Immunol. 1993;93:265–8. PubMedCrossRef

34.

Druet E, Praddaude F, Druet P, Dietrich G. Non-immunoglobulin serum proteins prevent the binding of IgG from normal rats and from rats with Th2-mediated autoimmune glomerulonephritis to various autoantigens including glomerular antigens. Eur J Immunol. 1998;28:183–92. CrossRefPubMed

35.

McIntyre JA, Hamilton RL, DeKosky ST. Redox-reactive autoantibodies in cerebrospinal fluids. Ann N Y Acad Sci. 2007;1109:296–302. CrossRefPubMed

36.

Omersel J, Jurgec I, Cucnik S, Kveder T, Rozman B, Sodin-Semrl S, et al. Autoimmune and proinflammatory activity of oxidized immunoglobulins. Autoimmun Rev. 2008;7:523–9. CrossRefPubMed

37.

McIntyre JA, Faulk WP. Redox-reactive autoantibodies: biochemistry, characterization, and specificities. Clin Rev Allergy Immunol. 2009;37:49–54. CrossRefPubMed

38.

McIntyre JA, Wagenknecht DR, Faulk WP. Autoantibodies unmasked by redox reactions. J Autoimmun. 2005;24:311–7. CrossRefPubMed

39.

McIntyre JA, Wagenknecht DR, Faulk WP. Redox-reactive autoantibodies: detection and physiological relevance. Autoimmun Rev. 2006;5:76–83. CrossRefPubMed

Titel: Natural Hidden Autoantibodies to Tissue Transglutaminase Cross-React with Fibrinogen
verfasst von: Ingrid M. Zöller-Utz
Birgit Esslinger
Anja Schulze-Krebs
Walburga Dieterich
Publikationsdatum: 01.03.2010
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 2/2010
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-009-9347-z

Neu im Fachgebiet Innere Medizin

09.06.2023 | Thrombozytenaggregationshemmer | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Natural Hidden Autoantibodies to Tissue Transglutaminase Cross-React with Fibrinogen

Abstract

Introduction

Methods

Results and discussion

Conclusion

Neu im Fachgebiet Innere Medizin

Plättchenhemmer plus Opioid: Wie riskant ist das?

Komorbiditäten beeinträchtigen Therapieansprechen bei RA

Kann das Darmmikrobiom zum Sport motivieren?

Radioligandentherapie des mCRPC erhält Lebensqualität

Update Innere Medizin

Springer Medizin

Abstract

Introduction

Methods

Results and discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

IL-17 Contributes to the Development of Chronic Rejection in a Murine Heart Transplant Model

Leukocyte Adhesion Deficiency Type II: Long-Term Follow-Up and Review of the Literature

Frequency of Treg Cells Is Reduced in CVID Patients with Autoimmunity and Splenomegaly and Is Associated with Expanded CD21lo B Lymphocytes

Chronic Inflammatory Bowel Disease as Key Manifestation of Atypical ARTEMIS Deficiency

Association of CTLA4 Gene Polymorphism in Iranian Patients with Ankylosing Spondylitis

Th17 Cells Facilitate the Humoral Immune Response in Patients with Acute Viral Myocarditis

Neu im Fachgebiet Innere Medizin

Plättchenhemmer plus Opioid: Wie riskant ist das?

Komorbiditäten beeinträchtigen Therapieansprechen bei RA

Kann das Darmmikrobiom zum Sport motivieren?

Radioligandentherapie des mCRPC erhält Lebensqualität

Update Innere Medizin